"Oxazolidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.
| Descriptor ID |
D023303
|
| MeSH Number(s) |
D03.383.129.462.600
|
| Concept/Terms |
Oxazolidin-2-one- Oxazolidin-2-one
- Oxazolidin 2 one
- 2-oxazolidinone
- 2 oxazolidinone
- 2-Oxazolidone
- 2 Oxazolidone
- 1,3-Oxazolidin-2-one
- 1,3 Oxazolidin 2 one
- 1,3-Oxazolidine-2-one
- 1,3 Oxazolidine 2 one
|
Below are MeSH descriptors whose meaning is more general than "Oxazolidinones".
Below are MeSH descriptors whose meaning is more specific than "Oxazolidinones".
This graph shows the total number of publications written about "Oxazolidinones" by people in this website by year, and whether "Oxazolidinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 3 | 0 | 3 |
| 2003 | 7 | 0 | 7 |
| 2004 | 2 | 0 | 2 |
| 2005 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 4 | 0 | 4 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 3 | 1 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oxazolidinones" by people in Profiles.
-
Antimicrobial Susceptibility Testing for Enterococci. J Clin Microbiol. 2022 09 21; 60(9):e0084321.
-
Antibacterial Activity of Tedizolid, a Novel Oxazolidinone Against Methicillin-Resistant Staphylococcus aureus: A Systematic Review and Meta-Analysis. Microb Drug Resist. 2019 Nov; 25(9):1330-1337.
-
In vitro activity of tedizolid and comparator agents against clinical Gram-positive isolates recovered from patients with cancer. Diagn Microbiol Infect Dis. 2018 Aug; 91(4):351-353.
-
A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Aug 15; 120(4):569-576.
-
Cadazolid for the treatment of Clostridium difficile. Expert Opin Investig Drugs. 2017 Apr; 26(4):509-514.
-
Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017 01; 33(1):1-7.
-
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Feb 01; 119(3):388-396.
-
Novel drugs against tuberculosis: a clinician's perspective. Eur Respir J. 2015 Apr; 45(4):1119-31.
-
Linezolid in the treatment of drug-resistant tuberculosis: the way forward? Int J Tuberc Lung Dis. 2014 Jun; 18(6):631-2.
-
In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients. J Antibiot (Tokyo). 2014 Jul; 67(7):505-9.